



Core BURN Product References

Alasbahi RH, Melzig MF. *Plectranthus barbatus*: a review of phytochemistry, ethnobotanical uses and pharmacology - Part 1. *Planta Med.* 2010 May;76(7):653-61.

Alasbahi RH, Melzig MF. Forskolin and derivatives as tools for studying the role of cAMP. *Pharmazie.* 2012 Jan;67(1):5-13.

Godard MP, et al. Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. *Obes Res.* 2005 Aug;13(8):1335-43.

Henderson S, et al. Effects of *coleus forskohlii* supplementation on body composition and hematological profiles in mildly overweight women. *J Int Soc Sports Nutr.* 2005 Dec 9;2:54-62.

Tamboli ET, et al. Metabolic diversity in *Coleus forskohlii* Briq. of Indian subcontinent. *Nat Prod Res.* 2013;27(19):1737-42.

Greenway FL, et al. Topical fat reduction. *Obes Res.* 1995 Nov;3 Suppl 4:561S-568S.

Shivaprasad HN, et al. Effect of *Coleus forskohlii* extract on cafeteria diet induced obesity in rats. *Pharmacognosy Res.* 2014 Jan;6(1):42-5.

Higgins HL, Means JH. The effect of certain drugs on the respiratory and gaseous metabolism in normal human subjects. *J Pharmacol Exp Ther* 1915;7:1-9.

Dulloo AG, Geissler CA, Horton T, Collins A, Miller DS. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. *Am J Clin Nutr* 1989;49:44 – 50.

Astrup A, Buemann B, Christensen NJ, et al. The effect of ephedrine/ caffeine mixtures on energy expenditure and body composition in obese women. *Metabolism* 1992;41:686 – 8.

Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? *Metabolism* 1992;41:1233– 41.

Dulloo AG, Miller DS. Aspirin as a promoter of ephedrine-induced thermogenesis: potential use in the treatment of obesity. *Am J Clin Nutr* 1987;45:564 –9.

Crush It

www.corenutrionals.com

Dulloo AG, Miller DS. The thermogenic properties of ephedrine/ methylxanthine mixtures: human studies. *Int J Obes* 1986;10:467– 81. Astrup A, Toubro S, Thorbek G, Cannon S, Hein P, Madsen J.

Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. *Metabolism* 1991;40:323–9.

Bracco D, Ferrarra J-M, Arnaud MJ, Jéquier E, Schutz Y. Effects of caffeine on energy metabolism, heart rate and methylxanthine metabolism in lean and obese women. *Am J Physiol* 1995;269:E671– 8.

Bellet S, Kershbaum A, Finck EM. Response of free fatty acids to coffee and caffeine. *Metabolism* 1968;17:702–7.

Bellet S, Roman L, de Castro O, Kim KE, Kershbaum A. Effect of coffee ingestion on catecholamine release. *Metabolism* 1969;18:288 – 91.

Butcher RW, Baird CE, Sutherland EW. Effects of lipolytic and antilipolytic substances on adenosine 3',5'-monophosphate levels in isolated fat cells. *J Biol Chem* 1968;243:1705–12.

Sidossis LS, Coggan AR, Gastaldelli A, Wolfe RR. A new correction factor for use in tracer estimations of plasma fatty acid oxidation. *Am J Physiol* 1995;269:E649 –56.

Wolfe RR. Tracers in metabolic research: radioisotopes and stable isotopes/mass spectrometry methods. New York: Liss, 1984.

Ochiai R, Jokura H, Suzuki A, Tokimitsu I, Ohishi M, Komai N, Rakugi H, Ogihara T. Green coffee bean extract improves human vasoreactivity. *Hypertens Res.* 2004;27:731–7. Medline

Shimoda H, Seki E, Aitani M. Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice. *BMC Complement Altern Med.* 2006;6:1–9.

Blum J, Lemaire B, Lafay S. Effect of a green decaffeinated coffee extract on glycaemia. *NutraFoods Res.* 2007;6:13–7.

Song, Y.; Wang, H. J.; Ma, J.; Wang, Z. *PLoS One* 2013, 8, 53069. Bolton, J. L.; Smith, S. H.; Huff, N. C.; Gilmour, M. I.; Foster, W. *FASEB J.* 2012, 26, 474–454.

Xia, W.; Sun, C.; Zhao, Y.; Wu, L. *Phytomedicine* 2011, 18, 516– 520. Seo, D. C.; Niu, J. *Int. J. Behav. Med.* 2013, Jun 7.

Suzuki, Y.; Miyoshim, N.; Isemura, M. *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* 2012, 88, 88–101

Bazzano, L. A.; Serdula, M. K.; Liu, S. *Curr. Atheroscler. Rep.* 2003, 5, 492–499.

Wu, S.; Deng, F.; Hao, Y.; Shima, M.; Wang, X.; Zheng, C; Wei, H; Lv, H; Lu, X; Huang, J; Qin, Y; Guo, X. *J. Hazard. Mater.* 2013, 260C, 183191.

Boyle, K. E.; Zheng, D.; Anderson, E. J.; Neuffer, P. D.; Houmard, J. A. *Int. J. Obes. (Lond)* 2012, 36, 1025–1031.

Xu, X.; Yavar, Z.; Verdin, M.; Ying, Z.; Mihai, G.; Kampfrath, T.; Wang, A.; Zhong, M.; Lippmann, M.; Chen, L. C.; Rajagopalan, S.; Sun, Q. *Arterioscler. Thromb. Vase. Biol.* 2010, 30, 2518–2527.

Ven Murthy MR, et al. Scientific basis for the use of Indian ayurvedic medicinal plants in the treatment of neurodegenerative disorders: ashwagandha. *Cent Nerv Syst Agents Med Chem.* (2010).

Shinomol GK, Muralidhara, Bharath MM. Exploring the role of "Brahmi" (*Bacopa monnieri* and *Centella asiatica*) in brain function and therapy. *Recent Pat Endocr Metab Immune Drug Discov.* (2011).

Singh RH, Narsimhamurthy K, Singh G. Neuronutrient impact of Ayurvedic Rasayana therapy in brain aging. *Biogerontology.* (2008).

Mukherjee S, et al. Evaluation of comparative free-radical quenching potential of Brahmi (*Bacopa monnieri*) and Mandookparni (*Centella asiatica*). *Ayu.* (2011).

Russo A, Borrelli F. *Bacopa monnieri*, a reputed nootropic plant: an overview. *Phytomedicine.* (2005).

Shinomol GK, Muralidhara. *Bacopa monnieri* modulates endogenous cytoplasmic and mitochondrial oxidative markers in prepubertal mice brain. *Phytomedicine.* (2011).

Chowdhuri DK, et al. Antistress effects of bacosides of *Bacopa monnieri*: modulation of Hsp70 expression, superoxide dismutase and cytochrome P450 activity in rat brain. *Phytother Res.* (2002).

Bhandari P, et al. Bacosterol glycoside, a new 13,14-seco-steroid glycoside from *Bacopa monnieri*. *Chem Pharm Bull (Tokyo).* (2006).

Ghosh T, Maity TK, Singh J. Antihyperglycemic activity of bacosine, a triterpene from *Bacopa monnieri*, in alloxan-induced diabetic rats. *Planta Med.* (2011).

Bhandari P, et al. A rapid RP-HPTLC densitometry method for simultaneous determination of major flavonoids in important medicinal plants. *J Sep Sci.* (2007).



Bhandari P, et al. Silica-based monolithic column with evaporative light scattering detector for HPLC analysis of bacosides and apigenin in *Bacopa monnieri*. *J Sep Sci*. (2009).

Deb DD, et al. In vitro safety evaluation and anticlastogenic effect of BacoMind on human lymphocytes. *Biomed Environ Sci*. (2008).

Murthy PB, et al. Estimation of twelve bacopa saponins in *Bacopa monnieri* extracts and formulations by high-performance liquid chromatography. *Chem Pharm Bull (Tokyo)*. (2006).

Deepak M, et al. Quantitative determination of the major saponin mixture bacoside A in *Bacopa monnieri* by HPLC. *Phytochem Anal*. (2005).

Phrompittayarat W, et al. Stability studies of saponins in *Bacopa monnieri* dried ethanolic extracts. *Planta Med*. (2008).

Sairam K, et al. Prophylactic and curative effects of *Bacopa monniera* in gastric ulcer models. *Phytomedicine*. (2001).

Goel RK, et al. In vitro evaluation of *Bacopa monniera* on anti- *Helicobacter pylori* activity and accumulation of prostaglandins. *Phytomedicine*. (2003).

Dorababu M, et al. Effect of *Bacopa monniera* and *Azadirachta indica* on gastric ulceration and healing in experimental NIDDM rats. *Indian J Exp Biol*. (2004).

Charles PD, et al. *Bacopa monniera* leaf extract up-regulates tryptophan hydroxylase (TPH2) and serotonin transporter (SERT) expression: implications in memory formation. *J Ethnopharmacol*. (2011).

Rajan KE, et al. Attenuation of 1-(m-chlorophenyl)-biguanide induced hippocampus-dependent memory impairment by a standardised extract of *Bacopa monniera* (BESEB CDRI-08). *Neurochem Res*. (2011).

SC, Leal MB, Limberger RP. 2008. Concentrations of p-synephrine in fruits and leaves of *Citrus* species (Rutaceae) and the acute toxicity testing of *Citrus aurantium* extract and p-synephrine. *Food Chem. Toxicol*. 46: 2770-2775.

Arbo MD, Schmitt GC, Limberger MF, Charão MF, Moro AM, Ribeiro GL, Dallegre E, Garcia SC, Leal MB, Limberger RP. 2009. Subchronic toxicity of *Citrus aurantium* L. (Rutaceae) extract and p- synephrine in mice. *Regulatory Toxicol. Pharmacol*. 54: 114-117. Synephrine Octopamine Caffeine HRA Page 37 of 49 File Number: 172091

Crush It

www.corenutrionals.com

Astrup A, Breum L, Toubro S, Hein P, Quaade F. 1992. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. *Int. J. Obes. Relat. Metab. Disord.* 16(4): 269-277. Astrup A, Toubro S. 1993. Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. *Int. J. Obes. Relat. Metab. Disord.* 17(Suppl. 1): S41-S43.

Astrup A, Breum L, Toubro S. 1995. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. *Obesity Res.*3(Suppl. 4): 537S-540S. Avula B, Upparapalli SK, Navarette A, Khan IA. 2005. Simultaneous quantification of adrenergic amines and flavonoids in *C. aurantium*, various Citrus species, and dietary supplements by liquid chromatography. *J. AOAC Int.* 88(6): 1593-1606.

Tang L. L., Wang R., Tang X. C. (2005). Effects of huperzine A on secretion of nerve growth factor in cultured rat cortical astrocytes and neurite outgrowth in rat PC12 cells. *Acta Pharmacol. Sin.* 26, 673–67810.

Tuszynski M. H., Sang H., Yoshida K., Gage F. H. (1991). Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. *Ann. Neurol.* 30, 625–63610.

Wang C. Y., Zheng W., Wang T., Xie J. W., Wang S. L., Zhao B. L., et al. (2011). Huperzine A activates Wnt/ β -catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model. *Neuropsychopharmacology* 36, 1073–108910.

Wang L. M., Han Y. F., Tang X. C. (2000). Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. *Eur. J. Pharmacol.* 398, 65–7210.

Wang R., Xiao X. Q., Tang X. C. (2001a). Huperzine A attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells. *Neuroreport* 12, 2629–2634.

Wang R., Zhang H. Y., Tang X. C. (2001b). Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta- amyloid protein-(1–40) in rat. *Eur. J. Pharmacol.* 421, 149–15610.1016/S0014-2999(01)01030-5.

Wang X. D., Zhang J. M., Yang H. H., Hu G. Y. (1999). Modulation of NMDA receptor by huperzine A in rat cerebral cortex. *Acta Pharmacol. Sin.* 20, 31–35.

Wang Y. E., Yue D. X., Tang X. C. (1986). Anti-cholinesterase activity of huperzine A. [Article in Chinese]. *Zhongguo Yao Li Xue Bao* 7, 110–113.